thyromimetic

{{multiple image

| align = right

| direction = vertical

| width = 200

| image1 = Triiodothyronine 200.svg

| caption1 = Triiodothyronine, a native thyroid hormone

| image2 = Sobetirome v2.svg

| caption2 = Sobetirome

| image3 = Omzotirome.svg

| caption3 = Omzotirome

| image4 = Eprotirome.svg

| caption4 = Eprotirome

| image5 = VK2809.svg

| caption5 = VK2809

| image6 = Resmetirom skeletal.svg

| caption6 = Resmetirom

}}

Thyromimetic drugs are synthetic agonists of the thyroid hormone receptor's isoforms TR α1, TRα2, TRβ1, or TRβ2, mimicking some or all of the effects of endogenously produced thyroid hormones that regulate metabolism.{{cite journal |last1=Unnikrishnan |first1=A. G. |last2=Baruah |first2=Manash |last3=Kalra |first3=Sanjay |title=Thyromimetics: What does the future hold? |journal=Indian Journal of Endocrinology and Metabolism |date=December 2012 |volume=16 |issue=Suppl 2 |pages=S159–S161 |doi=10.4103/2230-8210.104029 |pmid=23565368 |pmc=3603016 |issn=2230-8210 |doi-access=free }}{{cite book |last1=Devereaux |first1=Jordan |last2=Ferrara |first2=Skylar J. |last3=Scanlan |first3=Thomas S. |chapter=Quantification of Thyromimetic Sobetirome Concentration in Biological Tissue Samples |title=Thyroid Hormone Nuclear Receptor |series=Methods in Molecular Biology |date=2018 |volume=1801 |pages=193–206 |doi=10.1007/978-1-4939-7902-8_16 |url=https://link.springer.com/protocol/10.1007/978-1-4939-7902-8_16 |publisher=Springer |isbn=978-1-4939-7901-1 |language=en}} Some thyromimetic drugs are selective for various of these receptors over others, enabling more targeted effects and reducing toxicity. Thyromimetics selective for TRβ—including eprotirome,{{cite journal |last1=Saponaro |first1=Federica |last2=Sestito |first2=Simona |last3=Runfola |first3=Massimiliano |last4=Rapposelli |first4=Simona |last5=Chiellini |first5=Grazia |title=Selective Thyroid Hormone Receptor-Beta (TRβ) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders |journal=Frontiers in Medicine |date=2020 |volume=7 |page=331 |doi=10.3389/fmed.2020.00331 |issn=2296-858X |doi-access=free |pmid=32733906 |pmc=7363807 }} sobetirome,{{cite journal |last1=Tancevski |first1=Ivan |last2=Demetz |first2=Egon |last3=Eller |first3=Philipp |title=Sobetirome: A Selective Thyromimetic for the Treatment of Dyslipidemia |journal=Recent Patents on Cardiovascular Drug Discovery |date=1 January 2011 |volume=6 |issue=1 |pages=16–19 |doi=10.2174/157489011794578473 |url=https://www.ingentaconnect.com/content/ben/prc/2011/00000006/00000001/art00003|url-access=subscription }} resmetirom,{{cite journal |last1=Alkhouri |first1=Naim |title=Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196) |journal=Expert Opinion on Investigational Drugs |date=1 February 2020 |volume=29 |issue=2 |pages=99–101 |doi=10.1080/13543784.2020.1708899 |language=en |issn=1354-3784|doi-access=free }} and the prodrug VK2809—have been investigated for the treatment of non-alcoholic fatty liver disease, dyslipidemia, and other metabolic and neurodegenerative diseases.

References

{{reflist}}

Further reading

  • {{cite journal |last1=Yehuda-Shnaidman |first1=Einav |last2=Kalderon |first2=Bella |last3=Bar-Tana |first3=Jacob |title=Thyroid Hormone, Thyromimetics, and Metabolic Efficiency |journal=Endocrine Reviews |date=2014 |volume=35 |issue=1 |pages=35–58 |doi=10.1210/er.2013-1006|doi-access=free }}

Category:Thyroid hormone receptor agonists